Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

 Breaking News
  • No posts were found

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials
Non Alcoholic Fatty Liver Disease (NAFLD) companies are Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Terns, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others.

(Albany, United States) As per DelveInsight’s assessment, globally, Non Alcoholic Fatty Liver Disease (NAFLD) pipeline constitutes 80+ key companies continuously working towards developing 100+ Non Alcoholic Fatty Liver Disease (NAFLD) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Alcoholic Fatty Liver Disease (NAFLD) Market.

The Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for Sample Report here @ Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis

 

Some of the key takeaways from the Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Report:

  • NAFLD Companies across the globe are diligently working toward developing novel Non Alcoholic Fatty Liver Disease (NAFLD) treatment therapies with a considerable amount of success over the years. 
  • Non Alcoholic Fatty Liver Disease (NAFLD) companies working in the treatment market are Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others, are developing therapies for the Non Alcoholic Fatty Liver Disease (NAFLD) treatment.
  • Emerging Non Alcoholic Fatty Liver Disease (NAFLD) therapies such as MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others are expected to have a significant impact on the Non Alcoholic Fatty Liver Disease (NAFLD) market in the coming years.
  • On April 2024, Akero Therapeutics, Inc announced results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • On December 2023, Madrigal Pharmaceuticals, Inc announced results of a 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

 

Non Alcoholic Fatty Liver Disease (NAFLD) Overview

Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by the accumulation of fat in the liver of individuals who consume little to no alcohol. NAFLD encompasses a spectrum of liver conditions, ranging from simple fatty liver (steatosis) to more severe forms like non-alcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage. Risk factors for NAFLD include obesity, insulin resistance, type 2 diabetes, high cholesterol, and metabolic syndrome. The exact cause of NAFLD is not fully understood but is believed to involve a combination of genetic, environmental, and lifestyle factors.

NAFLD often presents without noticeable symptoms in its early stages, but as the condition progresses, individuals may experience fatigue, abdominal discomfort, and enlargement of the liver. Diagnosis typically involves imaging studies such as ultrasound, CT scan, or MRI, along with blood tests to assess liver function and rule out other liver diseases.

Management of NAFLD primarily focuses on lifestyle interventions, including weight loss, regular exercise, and dietary changes aimed at reducing fat accumulation in the liver and improving metabolic health. For individuals with NASH or advanced NAFLD, additional treatments such as medications targeting liver inflammation or fibrosis may be considered. Close monitoring and management of NAFLD are essential to prevent progression to more severe liver complications, including cirrhosis and liver failure.

 

Get a Free Sample PDF Report to know more about Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutic Assessment @ Non Alcoholic Fatty Liver Disease (NAFLD) Treatment Market

 

Non Alcoholic Fatty Liver Disease (NAFLD) Route of Administration

Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Non Alcoholic Fatty Liver Disease (NAFLD) Molecule Type

Non Alcoholic Fatty Liver Disease (NAFLD) Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutics Assessment

  • Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Product Type
  • Non Alcoholic Fatty Liver Disease (NAFLD) By Stage and Product Type
  • Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Route of Administration
  • Non Alcoholic Fatty Liver Disease (NAFLD) By Stage and Route of Administration
  • Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Molecule Type
  • Non Alcoholic Fatty Liver Disease (NAFLD) by Stage and Molecule Type

 

DelveInsight’s Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Report covers around 100+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Non Alcoholic Fatty Liver Disease (NAFLD) product details are provided in the report. Download the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report to learn more about the emerging Non Alcoholic Fatty Liver Disease (NAFLD) therapies @ Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and FDA Approvals

 

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis:

The Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non Alcoholic Fatty Liver Disease (NAFLD) with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Alcoholic Fatty Liver Disease (NAFLD) Treatment.
  • Non Alcoholic Fatty Liver Disease (NAFLD) key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non Alcoholic Fatty Liver Disease (NAFLD) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Alcoholic Fatty Liver Disease (NAFLD) market.

 

Download Sample PDF Report to know more about Non Alcoholic Fatty Liver Disease (NAFLD) drugs and therapies @ Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market

  

Scope of Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Drug Insight    

  • Coverage: Global
  • Key Non Alcoholic Fatty Liver Disease (NAFLD) Companies: Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others.
  • Key Non Alcoholic Fatty Liver Disease (NAFLD) Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others.
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Assessment: Non Alcoholic Fatty Liver Disease (NAFLD) current marketed and Non Alcoholic Fatty Liver Disease (NAFLD) emerging therapies
  • Non Alcoholic Fatty Liver Disease (NAFLD) Market Dynamics: Non Alcoholic Fatty Liver Disease (NAFLD) market drivers and Non Alcoholic Fatty Liver Disease (NAFLD) market barriers 

 

Request for Sample PDF Report for Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment and clinical trials @ Non Alcoholic Fatty Liver Disease (NAFLD) Drugs and Therapies

 

Table of Contents

  1. Non Alcoholic Fatty Liver Disease (NAFLD) Report Introduction
  2. Non Alcoholic Fatty Liver Disease (NAFLD) Executive Summary
  3. Non Alcoholic Fatty Liver Disease (NAFLD) Overview       
  4. Non Alcoholic Fatty Liver Disease (NAFLD)- Analytical Perspective In-depth Commercial Assessment
  5. Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutics
  6. Non Alcoholic Fatty Liver Disease (NAFLD) Late Stage Products (Phase II/III)
  7. Non Alcoholic Fatty Liver Disease (NAFLD) Mid Stage Products (Phase II)
  8. Non Alcoholic Fatty Liver Disease (NAFLD) Early Stage Products (Phase I)
  9. Non Alcoholic Fatty Liver Disease (NAFLD) Preclinical Stage Products
  10. Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Assessment
  11. Non Alcoholic Fatty Liver Disease (NAFLD) Inactive Products
  12. Company-University Collaborations (Licensing/Partnering) Analysis
  13. Non Alcoholic Fatty Liver Disease (NAFLD) Companies
  14. Non Alcoholic Fatty Liver Disease (NAFLD) Key Products
  15. Non Alcoholic Fatty Liver Disease (NAFLD) Unmet Needs
  16. 16 . Non Alcoholic Fatty Liver Disease (NAFLD) Market Drivers and Barriers
  17. Non Alcoholic Fatty Liver Disease (NAFLD) Future Perspectives and Conclusion
  18. Non Alcoholic Fatty Liver Disease (NAFLD) Analyst Views
  19. Appendix
  20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

Categories